Speed and Discipline: Enovis’ Roadmap to Growth

Over the last half-decade, Enovis has evolved into one of the most exciting companies in orthopedics. Its aggressive M&A strategy and entrepreneurial culture have Enovis on the cusp of $1 billion in annual reconstructive sales. For context, joint replacement made up just 22% of total company sales in 2019. It climbed to 34% by the end of...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

ME

Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.



Contact Us

0